Precision Medicine and Immunotherapy in mNSCLC: Bridging Gaps for Patients Without Driver Mutations

Experts discuss the significance of treatment selection in patients with driver mutations.

Experts share insights on the use chemotherapy and immunotherapy in driver-negative patients, along with the use of PD-L1 inhibitors.

Experts explore the utilization of next-generation sequencing, including liquid biopsies, in mNSCLC Diagnosis.

Experts examine primary and acquired resistance mechanisms in immunotherapy, while promoting realistic treatment strategies.

Professionals deliberate the progression of Immuno-Oncology combinations while also engaging in conversations regarding the issue of immunotherapy resistance.

Specialists discuss adverse reactions to immunotherapy and explore the importance of CTLA-4 inhibitors in mNSCLC treatment.

Specialists evaluate their clinical strategies for managing second-line driver-negative and initial PD-L1 negative patients.

Specialists address the intricate factors between comorbidities, efficacy, and tolerance, which influence their treatment approaches at the time of diagnosis.

A conversation on patient tolerance of CTLA-4 immunotherapies, alongside an exploration of treatment-related adverse reactions is discussed by a panel of experts.

Specialists engage in a conversation regarding the treatment duration and the effectiveness of the current two-year approach.

Experts address the impact of platinum shortages, 4-cycle platinum chemotherapy, and available treatments beyond platinum chemotherapy.

Providers speak to the importance of encouraging patients to self-report adverse reactions and participate in shared decision making.

Specialists delve into strategies for monitoring treatment response and the importance of assessing symptoms during the initial three treatment cycles.

Experts emphasize the crucial role of swift diagnostic testing, especially through liquid biopsies.

Panelists share their final thoughts on staying updated with the latest advancements in the field.